IL-17E/IL-25 Antibody (68C1039.2) - BSA Free

Novus Biologicals | Catalog # NB100-56541

Novus Biologicals
100% Guarantee

Key Product Details

Species Reactivity

Validated:

Human, Mouse

Cited:

Human, Mouse

Applications

Validated:

Immunohistochemistry, Immunohistochemistry-Paraffin, Western Blot, Immunocytochemistry/ Immunofluorescence

Cited:

Immunohistochemistry-Paraffin, Western Blot, Immunocytochemistry/ Immunofluorescence, IF/IHC

Label

Unconjugated

Antibody Source

Monoclonal Mouse IgG1 Clone # 68C1039.2

Format

BSA Free
View all IL-17E/IL-25 Primary Antibodies »

Product Specifications

Immunogen

Amino acids 115-132 of human IL-17E (isoform CRA_a) were used as immunogen for this antibody.

Clonality

Monoclonal

Host

Mouse

Isotype

IgG1

Theoretical MW

20 kDa.
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.

Scientific Data Images for IL-17E/IL-25 Antibody (68C1039.2) - BSA Free

Western Blot: IL-17E/IL-25 Antibody (68C1039.2)BSA Free [NB100-56541]

Western Blot: IL-17E/IL-25 Antibody (68C1039.2)BSA Free [NB100-56541]

Western Blot: IL-17E/IL-25 Antibody (68C1039.2) [NB100-56541] - Analysis of IL-17E using IL-17E monoclonal antibody. Mouse testis lysate probed with IL-17E antibody at 2 ug/mL.
Immunohistochemistry: IL-17E/IL-25 Antibody (68C1039.2) - BSA Free [NB100-56541]

Immunohistochemistry: IL-17E/IL-25 Antibody (68C1039.2) - BSA Free [NB100-56541]

IL-17E-IL-25-Antibody-68C1039-2-BSA-Free-Immunohistochemistry-NB100-56541-img0008.jpg
Immunohistochemistry-Paraffin: IL-17E/IL-25 Antibody (68C1039.2) - BSA Free [NB100-56541]

Immunohistochemistry-Paraffin: IL-17E/IL-25 Antibody (68C1039.2) - BSA Free [NB100-56541]

Immunohistochemistry-Paraffin: IL-17E/IL-25 Antibody (68C1039.2) [NB100-56541] - Tissue section of mouse liver using IL17E/IL25 antibody clone 68C1039.2 at 1:150. The antibody generated a diffused cytoplasmic staining in the hepatocytes with a very strong signal in the sinusoidal endothelial cells.
Immunohistochemistry-Paraffin: IL-17E/IL-25 Antibody (68C1039.2) - BSA Free [NB100-56541]

Immunohistochemistry-Paraffin: IL-17E/IL-25 Antibody (68C1039.2) - BSA Free [NB100-56541]

Immunohistochemistry-Paraffin: IL-17E/IL-25 Antibody (68C1039.2) [NB100-56541] - Tissue section of mouse kidney using IL17E/IL25 antibody clone 68C1039.2 at 1:150. The antibody generated a diffused cytoplasmic staining in the tubular and ductal epithelia cells, and a strong positivity in the inter-tubular/ductal blood vessels.
Immunohistochemistry-Paraffin: IL-17E/IL-25 Antibody (68C1039.2) - BSA Free [NB100-56541]

Immunohistochemistry-Paraffin: IL-17E/IL-25 Antibody (68C1039.2) - BSA Free [NB100-56541]

Immunohistochemistry-Paraffin: IL-17E/IL-25 Antibody (68C1039.2) [NB100-56541] - Adrenal cortex, Human
IL-17E/IL-25 Antibody (68C1039.2) - BSA Free

Western Blot: IL-17E/IL-25 Antibody (68C1039.2) - BSA Free [NB100-56541] -

Western Blot: IL-17E/IL-25 Antibody (68C1039.2) - BSA Free [NB100-56541] - IL25 upregulated GLI1 by inhibiting p-AMPK. (A) HT-29 cells were treated with cycloheximide (CHX, 50 μg/ml) for the indicated time, & cell lysates were analyzed by Western blotting with the indicated antibodies. (B) Western blotting of p-AMPK & AMPK in the WT & IL25KO AOM/DSS-induced tumor tissue. (C) The expression levels of GLI1, p-AMPK, & AMPK were examined in HT-29 & SW620 cells treated with recombinant IL25 in a time-dependent manner by Western blotting. (D, E) Western blotting of GLI1, p-AMPK, & AMPK in SW620 cells treated with AMPK activator A769662 & Metformin following IL25 treatment. (F) GLI1 expression was detected by immunofluorescence staining in SW620 cells treated with AMPK activator Metformin following IL25 treatment. (G) SW620 cells were treated with 10 μM MG132 & then incubated with or without 50 ng/ml recombinant IL25 & 1 mM Metformin, then immunoprecipitated with GLI1 antibody. GLI1 ubiquitination was determined using an anti-ubiquitin antibody. IP, immunoprecipitation. (H) Sphere formation analysis of SW620 cells treated with AMPK activator Metformin following IL25 treatment. Representative images (left) & the mean numbers & sphere size (right) of spheres are shown. Data present as mean ± SEM; *p <0.05, **p <0.01, ***p <0.001. Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/35359953), licensed under a CC-BY license. Not internally tested by Novus Biologicals.
IL-17E/IL-25 Antibody (68C1039.2) - BSA Free

Western Blot: IL-17E/IL-25 Antibody (68C1039.2) - BSA Free [NB100-56541] -

Western Blot: IL-17E/IL-25 Antibody (68C1039.2) - BSA Free [NB100-56541] - IL25 upregulated GLI1 by inhibiting p-AMPK. (A) HT-29 cells were treated with cycloheximide (CHX, 50 μg/ml) for the indicated time, & cell lysates were analyzed by Western blotting with the indicated antibodies. (B) Western blotting of p-AMPK & AMPK in the WT & IL25KO AOM/DSS-induced tumor tissue. (C) The expression levels of GLI1, p-AMPK, & AMPK were examined in HT-29 & SW620 cells treated with recombinant IL25 in a time-dependent manner by Western blotting. (D, E) Western blotting of GLI1, p-AMPK, & AMPK in SW620 cells treated with AMPK activator A769662 & Metformin following IL25 treatment. (F) GLI1 expression was detected by immunofluorescence staining in SW620 cells treated with AMPK activator Metformin following IL25 treatment. (G) SW620 cells were treated with 10 μM MG132 & then incubated with or without 50 ng/ml recombinant IL25 & 1 mM Metformin, then immunoprecipitated with GLI1 antibody. GLI1 ubiquitination was determined using an anti-ubiquitin antibody. IP, immunoprecipitation. (H) Sphere formation analysis of SW620 cells treated with AMPK activator Metformin following IL25 treatment. Representative images (left) & the mean numbers & sphere size (right) of spheres are shown. Data present as mean ± SEM; *p <0.05, **p <0.01, ***p <0.001. Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/35359953), licensed under a CC-BY license. Not internally tested by Novus Biologicals.
IL-17E/IL-25 Antibody (68C1039.2) - BSA Free

Western Blot: IL-17E/IL-25 Antibody (68C1039.2) - BSA Free [NB100-56541] -

Western Blot: IL-17E/IL-25 Antibody (68C1039.2) - BSA Free [NB100-56541] - IL25 upregulated GLI1 by inhibiting p-AMPK. (A) HT-29 cells were treated with cycloheximide (CHX, 50 μg/ml) for the indicated time, & cell lysates were analyzed by Western blotting with the indicated antibodies. (B) Western blotting of p-AMPK & AMPK in the WT & IL25KO AOM/DSS-induced tumor tissue. (C) The expression levels of GLI1, p-AMPK, & AMPK were examined in HT-29 & SW620 cells treated with recombinant IL25 in a time-dependent manner by Western blotting. (D, E) Western blotting of GLI1, p-AMPK, & AMPK in SW620 cells treated with AMPK activator A769662 & Metformin following IL25 treatment. (F) GLI1 expression was detected by immunofluorescence staining in SW620 cells treated with AMPK activator Metformin following IL25 treatment. (G) SW620 cells were treated with 10 μM MG132 & then incubated with or without 50 ng/ml recombinant IL25 & 1 mM Metformin, then immunoprecipitated with GLI1 antibody. GLI1 ubiquitination was determined using an anti-ubiquitin antibody. IP, immunoprecipitation. (H) Sphere formation analysis of SW620 cells treated with AMPK activator Metformin following IL25 treatment. Representative images (left) & the mean numbers & sphere size (right) of spheres are shown. Data present as mean ± SEM; *p <0.05, **p <0.01, ***p <0.001. Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/35359953), licensed under a CC-BY license. Not internally tested by Novus Biologicals.
IL-17E/IL-25 Antibody (68C1039.2) - BSA Free

Immunohistochemistry: IL-17E/IL-25 Antibody (68C1039.2) - BSA Free [NB100-56541] -

Immunohistochemistry: IL-17E/IL-25 Antibody (68C1039.2) - BSA Free [NB100-56541] - Overexpression of IL25 was found in CRC patients & predicts a poor prognosis. (A) Immunohistochemistry (IHC) staining of IL25 was performed in a tissue microarray consisting of 74 CRC tumor tissues & adjacent colon tissues (left). Statistical analysis of IL25 staining in adjacent specimens & CRC specimens (right). (B) Protein levels of IL25 were detected by Western blotting in normal intestinal cells (CCD841) & CRC cell lines (left). The right panel showed the quantitative analysis of the gray scan. The ImageJ software was used for gray scanning. (C) Representative images of IL25 IHC staining at different clinical stages (up). Correlation between IL25 expression & various clinical stages (down). (D) Overall survival curves of 49 CRC patients in correlation with intra-tumor IL25 IHC-scores. High IL25 expression was considered IHC-Score >6. The patients with CRC were divided into 2 groups according to the intra-tumor IL25 IHC-score: low group (n = 34), high group (n = 15). (E) Representative images of IL25 IHC staining from WT colon & AOM/DSS induced tumors on weeks 10 & 16 (down). Statistical analysis of IL25 staining in con colon, adjacent tissues, & AOM/DSS-induced CRC tissues (up). Data present as mean ± SEM; *p < 0.05, **p < 0.01, ***p < 0.001. Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/35359953), licensed under a CC-BY license. Not internally tested by Novus Biologicals.
IL-17E/IL-25 Antibody (68C1039.2) - BSA Free

Western Blot: IL-17E/IL-25 Antibody (68C1039.2) - BSA Free [NB100-56541] -

Western Blot: IL-17E/IL-25 Antibody (68C1039.2) - BSA Free [NB100-56541] - IL25 upregulated GLI1 by inhibiting p-AMPK. (A) HT-29 cells were treated with cycloheximide (CHX, 50 μg/ml) for the indicated time, & cell lysates were analyzed by Western blotting with the indicated antibodies. (B) Western blotting of p-AMPK & AMPK in the WT & IL25KO AOM/DSS-induced tumor tissue. (C) The expression levels of GLI1, p-AMPK, & AMPK were examined in HT-29 & SW620 cells treated with recombinant IL25 in a time-dependent manner by Western blotting. (D, E) Western blotting of GLI1, p-AMPK, & AMPK in SW620 cells treated with AMPK activator A769662 & Metformin following IL25 treatment. (F) GLI1 expression was detected by immunofluorescence staining in SW620 cells treated with AMPK activator Metformin following IL25 treatment. (G) SW620 cells were treated with 10 μM MG132 & then incubated with or without 50 ng/ml recombinant IL25 & 1 mM Metformin, then immunoprecipitated with GLI1 antibody. GLI1 ubiquitination was determined using an anti-ubiquitin antibody. IP, immunoprecipitation. (H) Sphere formation analysis of SW620 cells treated with AMPK activator Metformin following IL25 treatment. Representative images (left) & the mean numbers & sphere size (right) of spheres are shown. Data present as mean ± SEM; *p <0.05, **p <0.01, ***p <0.001. Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/35359953), licensed under a CC-BY license. Not internally tested by Novus Biologicals.
IL-17E/IL-25 Antibody (68C1039.2) - BSA Free

Immunohistochemistry: IL-17E/IL-25 Antibody (68C1039.2) - BSA Free [NB100-56541] -

Immunohistochemistry: IL-17E/IL-25 Antibody (68C1039.2) - BSA Free [NB100-56541] - Overexpression of IL25 was found in CRC patients & predicts a poor prognosis. (A) Immunohistochemistry (IHC) staining of IL25 was performed in a tissue microarray consisting of 74 CRC tumor tissues & adjacent colon tissues (left). Statistical analysis of IL25 staining in adjacent specimens & CRC specimens (right). (B) Protein levels of IL25 were detected by Western blotting in normal intestinal cells (CCD841) & CRC cell lines (left). The right panel showed the quantitative analysis of the gray scan. The ImageJ software was used for gray scanning. (C) Representative images of IL25 IHC staining at different clinical stages (up). Correlation between IL25 expression & various clinical stages (down). (D) Overall survival curves of 49 CRC patients in correlation with intra-tumor IL25 IHC-scores. High IL25 expression was considered IHC-Score >6. The patients with CRC were divided into 2 groups according to the intra-tumor IL25 IHC-score: low group (n = 34), high group (n = 15). (E) Representative images of IL25 IHC staining from WT colon & AOM/DSS induced tumors on weeks 10 & 16 (down). Statistical analysis of IL25 staining in con colon, adjacent tissues, & AOM/DSS-induced CRC tissues (up). Data present as mean ± SEM; *p < 0.05, **p < 0.01, ***p < 0.001. Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/35359953), licensed under a CC-BY license. Not internally tested by Novus Biologicals.
IL-17E/IL-25 Antibody (68C1039.2) - BSA Free

Western Blot: IL-17E/IL-25 Antibody (68C1039.2) - BSA Free [NB100-56541] -

Western Blot: IL-17E/IL-25 Antibody (68C1039.2) - BSA Free [NB100-56541] - IL25 upregulated GLI1 by inhibiting p-AMPK. (A) HT-29 cells were treated with cycloheximide (CHX, 50 μg/ml) for the indicated time, & cell lysates were analyzed by Western blotting with the indicated antibodies. (B) Western blotting of p-AMPK & AMPK in the WT & IL25KO AOM/DSS-induced tumor tissue. (C) The expression levels of GLI1, p-AMPK, & AMPK were examined in HT-29 & SW620 cells treated with recombinant IL25 in a time-dependent manner by Western blotting. (D, E) Western blotting of GLI1, p-AMPK, & AMPK in SW620 cells treated with AMPK activator A769662 & Metformin following IL25 treatment. (F) GLI1 expression was detected by immunofluorescence staining in SW620 cells treated with AMPK activator Metformin following IL25 treatment. (G) SW620 cells were treated with 10 μM MG132 & then incubated with or without 50 ng/ml recombinant IL25 & 1 mM Metformin, then immunoprecipitated with GLI1 antibody. GLI1 ubiquitination was determined using an anti-ubiquitin antibody. IP, immunoprecipitation. (H) Sphere formation analysis of SW620 cells treated with AMPK activator Metformin following IL25 treatment. Representative images (left) & the mean numbers & sphere size (right) of spheres are shown. Data present as mean ± SEM; *p <0.05, **p <0.01, ***p <0.001. Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/35359953), licensed under a CC-BY license. Not internally tested by Novus Biologicals.
IL-17E/IL-25 Antibody (68C1039.2) - BSA Free

Western Blot: IL-17E/IL-25 Antibody (68C1039.2) - BSA Free [NB100-56541] -

Western Blot: IL-17E/IL-25 Antibody (68C1039.2) - BSA Free [NB100-56541] - Overexpression of IL25 was found in CRC patients & predicts a poor prognosis. (A) Immunohistochemistry (IHC) staining of IL25 was performed in a tissue microarray consisting of 74 CRC tumor tissues & adjacent colon tissues (left). Statistical analysis of IL25 staining in adjacent specimens & CRC specimens (right). (B) Protein levels of IL25 were detected by Western blotting in normal intestinal cells (CCD841) & CRC cell lines (left). The right panel showed the quantitative analysis of the gray scan. The ImageJ software was used for gray scanning. (C) Representative images of IL25 IHC staining at different clinical stages (up). Correlation between IL25 expression & various clinical stages (down). (D) Overall survival curves of 49 CRC patients in correlation with intra-tumor IL25 IHC-scores. High IL25 expression was considered IHC-Score >6. The patients with CRC were divided into 2 groups according to the intra-tumor IL25 IHC-score: low group (n = 34), high group (n = 15). (E) Representative images of IL25 IHC staining from WT colon & AOM/DSS induced tumors on weeks 10 & 16 (down). Statistical analysis of IL25 staining in con colon, adjacent tissues, & AOM/DSS-induced CRC tissues (up). Data present as mean ± SEM; *p < 0.05, **p < 0.01, ***p < 0.001. Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/35359953), licensed under a CC-BY license. Not internally tested by Novus Biologicals.
IL-17E/IL-25 Antibody (68C1039.2) - BSA Free

Immunohistochemistry: IL-17E/IL-25 Antibody (68C1039.2) - BSA Free [NB100-56541] -

Immunohistochemistry: IL-17E/IL-25 Antibody (68C1039.2) - BSA Free [NB100-56541] - IL25 upregulated GLI1 by inhibiting p-AMPK. (A) HT-29 cells were treated with cycloheximide (CHX, 50 μg/ml) for the indicated time, & cell lysates were analyzed by Western blotting with the indicated antibodies. (B) Western blotting of p-AMPK & AMPK in the WT & IL25KO AOM/DSS-induced tumor tissue. (C) The expression levels of GLI1, p-AMPK, & AMPK were examined in HT-29 & SW620 cells treated with recombinant IL25 in a time-dependent manner by Western blotting. (D, E) Western blotting of GLI1, p-AMPK, & AMPK in SW620 cells treated with AMPK activator A769662 & Metformin following IL25 treatment. (F) GLI1 expression was detected by immunofluorescence staining in SW620 cells treated with AMPK activator Metformin following IL25 treatment. (G) SW620 cells were treated with 10 μM MG132 & then incubated with or without 50 ng/ml recombinant IL25 & 1 mM Metformin, then immunoprecipitated with GLI1 antibody. GLI1 ubiquitination was determined using an anti-ubiquitin antibody. IP, immunoprecipitation. (H) Sphere formation analysis of SW620 cells treated with AMPK activator Metformin following IL25 treatment. Representative images (left) & the mean numbers & sphere size (right) of spheres are shown. Data present as mean ± SEM; *p <0.05, **p <0.01, ***p <0.001. Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/35359953), licensed under a CC-BY license. Not internally tested by Novus Biologicals.
IL-17E/IL-25 Antibody (68C1039.2) - BSA Free

Western Blot: IL-17E/IL-25 Antibody (68C1039.2) - BSA Free [NB100-56541] -

Western Blot: IL-17E/IL-25 Antibody (68C1039.2) - BSA Free [NB100-56541] - IL25 upregulated GLI1 by inhibiting p-AMPK. (A) HT-29 cells were treated with cycloheximide (CHX, 50 μg/ml) for the indicated time, & cell lysates were analyzed by Western blotting with the indicated antibodies. (B) Western blotting of p-AMPK & AMPK in the WT & IL25KO AOM/DSS-induced tumor tissue. (C) The expression levels of GLI1, p-AMPK, & AMPK were examined in HT-29 & SW620 cells treated with recombinant IL25 in a time-dependent manner by Western blotting. (D, E) Western blotting of GLI1, p-AMPK, & AMPK in SW620 cells treated with AMPK activator A769662 & Metformin following IL25 treatment. (F) GLI1 expression was detected by immunofluorescence staining in SW620 cells treated with AMPK activator Metformin following IL25 treatment. (G) SW620 cells were treated with 10 μM MG132 & then incubated with or without 50 ng/ml recombinant IL25 & 1 mM Metformin, then immunoprecipitated with GLI1 antibody. GLI1 ubiquitination was determined using an anti-ubiquitin antibody. IP, immunoprecipitation. (H) Sphere formation analysis of SW620 cells treated with AMPK activator Metformin following IL25 treatment. Representative images (left) & the mean numbers & sphere size (right) of spheres are shown. Data present as mean ± SEM; *p <0.05, **p <0.01, ***p <0.001. Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/35359953), licensed under a CC-BY license. Not internally tested by Novus Biologicals.
IL-17E/IL-25 Antibody (68C1039.2) - BSA Free

Western Blot: Mouse Monoclonal IL-17E/IL-25 Antibody (68C1039.2) [IMGENEX: IMG-323A] [NB100-56541]

Mouse liver lysates probed with IL-17E/IL-25 Antibody at dilution 1:1000 in 1xTBST. Image from a verified customer review.

Applications for IL-17E/IL-25 Antibody (68C1039.2) - BSA Free

Application
Recommended Usage

Immunocytochemistry/ Immunofluorescence

reported in scientific literature (PMID 35359953)

Immunohistochemistry

1:100 - 1:500

Immunohistochemistry-Paraffin

reported in scientific literature (Terrier B et al)

Western Blot

1:100 - 1:250
Application Notes
The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.

Reviewed Applications

Read 1 review rated 4 using NB100-56541 in the following applications:

Formulation, Preparation, and Storage

Purification

Protein G purified

Formulation

PBS

Format

BSA Free

Preservative

0.05% Sodium Azide

Concentration

1.0 mg/ml

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.

Background: IL-17E/IL-25

A number of cytokines belonging to the interleukin (IL)-17 family have been identified, termed IL-17A-F. IL-17 is a potent proinflammatory cytokine that plays roles in a number of diseases including rheumatoid arthritis, multiple sclerosis, and promotion of tumor growth. IL-17E, C, and B are able to induce proinflammatory responses. However, they do not bind to the IL-17 receptor suggesting that an additional IL-17R related receptor may exist. Receptors for IL-17B and IL-17E have been independently isolated by Shi, et al and Lee, et al. and have been designated as EV127 (in mouse) and IL-17Rh1 (in human), respectively. IL-17E, also called IL-25, induces activation of NF-kB pathway and like IL-17 also induces production of IL-8.

Long Name

Interleukin 17E

Alternate Names

IL-25, IL17E, IL25

Entrez Gene IDs

64806 (Human); 140806 (Mouse)

Gene Symbol

IL25

UniProt

Q9H293

Additional IL-17E/IL-25 Products

Product Documents for IL-17E/IL-25 Antibody (68C1039.2) - BSA Free

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot or batch number in the search box below.

Download SDS

Product Specific Notices for IL-17E/IL-25 Antibody (68C1039.2) - BSA Free

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Citations for IL-17E/IL-25 Antibody (68C1039.2) - BSA Free

Customer Reviews for IL-17E/IL-25 Antibody (68C1039.2) - BSA Free (1)

4 out of 5
1 Customer Rating
5 Stars
0%
4 Stars
100%
3 Stars
0%
2 Stars
0%
1 Stars
0%

Have you used IL-17E/IL-25 Antibody (68C1039.2) - BSA Free?

Submit a review and receive an Amazon gift card!

$25/€18/£15/$25CAN/¥2500 Yen for a review with an image

$10/€7/£6/$10CAN/¥1110 Yen for a review without an image

Submit a review
Amazon Gift Card

Customer Images

Showing  1 - 1 of 1 review Showing All
Filter By:
Clear Filters X
  • IL-17E/IL-25 Antibody (68C1039.2) - BSA Free
    Name: Kamal Baral
    Application: Western Blot
    Sample Tested: mouse liver lysate
    Species: Mouse
    Verified Customer | Posted 10/21/2025
    Mouse liver lysates probed with IL-17E/IL-25 Antibody at dilution 1:1000 in 1xTBST.
    IL-17E/IL-25 Antibody (68C1039.2) - BSA Free NB100-56541

There are no reviews that match your criteria.

Showing  1 - 1 of 1 review Showing All

Protocols

View specific protocols for IL-17E/IL-25 Antibody (68C1039.2) - BSA Free (NB100-56541):

Immunohistochemistry-Paraffin Embedded Sections

Antigen Unmasking:
Bring slides to a boil in 10 mM sodium citrate buffer (pH 6.0) then maintain at a sub-boiling temperature for 10 minutes. Cool slides on bench-top for 30 minutes (keep slides in the sodium citrate buffer at all times).

Staining:
1. Wash sections in deionized water three times for 5 minutes each.
2. Wash sections in PBS for 5 minutes.
3. Block each section with 100-400 ul blocking solution (1% BSA in PBS) for 1 hour at room temperature.
4. Remove blocking solution and add 100-400 ul diluted primary antibody. Incubate overnight at 4 C.
5. Remove antibody solution and wash sections in wash buffer three times for 5 minutes each.
6. Add 100-400 ul HRP polymer conjugated secondary antibody. Incubate 30 minutes at room temperature.
7. Wash sections three times in wash buffer for 5 minutes each.
8. Add 100-400 ul DAB substrate to each section and monitor staining closely.
9. As soon as the sections develop, immerse slides in deionized water.
10. Counterstain sections in hematoxylin.
11. Wash sections in deionized water two times for 5 minutes each.
12. Dehydrate sections.
13. Mount coverslips.


Find general support by application which include: protocols, troubleshooting, illustrated assays, videos and webinars.

FAQs for IL-17E/IL-25 Antibody (68C1039.2) - BSA Free

Showing  1 - 2 of 2 FAQs Showing All

  • Q: Are the following monoclonals purified from ascites or from tissue culture supernatant? NB100-56541, NB100-56705, NB600-1298, NB100-56534, NB100-56505, NBP2-24873, NB600-1107, NBP2-24917, NB100-56524, NB100-56712

    A: These antibodies are all purified from tissue culture supernatant.

  • Q: Would you be able to tell me if this Ab has neutralizing capabilities? Has it been tested?

    A: This antibody has only been validated in Western blot and IHC on paraffin-embedded tissues. It has not been tested for its neutralizing capabilities.

  • Q: Are the following monoclonals purified from ascites or from tissue culture supernatant? NB100-56541, NB100-56705, NB600-1298, NB100-56534, NB100-56505, NBP2-24873, NB600-1107, NBP2-24917, NB100-56524, NB100-56712

    A: These antibodies are all purified from tissue culture supernatant.

  • Q: Would you be able to tell me if this Ab has neutralizing capabilities? Has it been tested?

    A: This antibody has only been validated in Western blot and IHC on paraffin-embedded tissues. It has not been tested for its neutralizing capabilities.

Showing  1 - 2 of 2 FAQs Showing All
View all FAQs for Antibodies